A Phase II 6-week, Randomized, Double-blinded, Placebo Controlled, Parallel Group Decentralised Clinical Trial to Evaluate Efficacy and Safety of Oral BI 1358894 in Patients With Major Depressive Disorder With Inadequate Response to Antidepressants
Latest Information Update: 15 May 2023
At a glance
- Drugs BI 1358894 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 01 Jun 2022 Status changed from active, no longer recruiting to discontinued.
- 18 May 2022 Planned End Date changed from 18 May 2022 to 1 Jun 2022.
- 18 May 2022 Status changed from suspended to active, no longer recruiting.